National Center for Advancing and Translational Sciences Genetic and Rare Diseases Information Center, a program of the National Center for Advancing and Translational Sciences

PIK3CA-related overgrowth spectrum


Información en español


Other Names:
PIK3CA-associated segmental overgrowth
Subtypes:

PIK3CA-related overgrowth spectrum (PROS) is a group of rare disorders that cause overgrowth of parts of the body, due to mutations in the PIK3CA gene. Specific disorders in this spectrum include:[1][2][3][4]
Signs and symptoms of PROS depend on the specific disorder present. Depending on the disorder, they can include having a larger-than-normal brain (megalencephaly), low muscle tone (hypotonia), seizures, intellectual disability, changes in the blood vessels (vascular system), and overgrowth of one area of the body (focal overgrowth) or of multiple areas of the body (segmental overgrowth), with normal growth elsewhere.[1]

PROS is usually caused by somatic mutations in the PIK3CA gene. These changes typically are only present in some cells or some areas of the body (called mosaicism), and are not known to be inherited. Rarely, PROS is caused by a de novo germline mutation, which is present in all cells of the body. The diagnosis of a PROS disorder can be confirmed with genetic testing of the PIK3CA gene. Treatment for a PROS disorder may involve surgical interventions, special education, and speech and physical therapies.[1]
Last updated: 7/10/2018

The signs and symptoms of PIK3CA-related overgrowth spectrum (PROS) vary depending on the particular disorder each person has. for example:

CLOVES syndrome
is associated with fatty (lipomatous) growths that typically affect the trunk; blood vessel differences (vascular malformations); patches or growths on the skin (epidermal nevi); and differences in the bones (skeletal system). Skeletal abnormalities can include a curve in the spine (scoliosis) and having very large fingers or toes (macrodactyly). Fibroadipose hyperplasia typically has signs and symptoms that are very similar to those of CLOVES syndrome.[1]

Megalencephaly-capillary malformation syndrome (MCAP syndrome) is associated with having a very large brain (megalencephaly) or having one half of the brain larger than expected (hemimegalencephaly).  It also causes differences in the smallest blood vessels, called the capillaries. Megalencephaly can cause symptoms including low muscle tone (hypotonia), seizures, and intellectual disability. Other features of MCAP syndrome may include having fingers or toes that are fused together (syndactyly), having extra fingers or toes (polydactyly), and being very flexible (joint hypermobility). Some people with MCAP syndrome may have heart anomalies.[1]

Hemihyperplasia‐multiple lipomatosis syndrome (HHML syndrome) is associated with non-progressive, asymmetrical, moderate overgrowth usually affecting the limbs. It is also associated with slow-growing, painless, subcutaneous lipomatous masses (made up of fat cells) distributed throughout the body. Vascular malformations may also be present.[5]

Facial infiltrating lipomatosis (FIL) causes overgrowth and enlargement of one side of the face. It can also cause mucosal neuromas (masses that grow from a nerve), hemimacroglossia (enlargement of half of the tongue), bone enlargement, and premature dental eruption.[4]

Because PROS causes cells of the body to grow and divide more quickly, there is an increased risk of cancer in people with some forms of PROS.[6] PIK3CA mutations are frequently found in the tumors of people without PROS in many cancers including colon, breast, brain, liver, stomach, and lung.[1]
Last updated: 7/10/2018

PIK3CA-related overgrowth spectrum (PROS) is caused by changes in the PIK3CA gene. When a genetic change causes a syndrome, it is also known as a mutation or pathogenic variant. The PIK3CA gene provides instructions to the body to make a protein that helps control the signaling of other proteins. This protein therefore helps many processes occur at the correct times including cell growth and division, cell movement, and cell survival. When there is a change in the PIK3CA gene, the body does not receive instructions to make the signaling protein correctly. This causes mistakes in cell growth and division and how long a cell survives. If cells are dividing too quickly or if they survive longer than they should, overgrowth of that part of the body can occur. This causes the signs and symptoms associated with PROS.[7]
Last updated: 1/29/2018

PIK3CA-related overgrowth spectrum (PROS) is not known to be inherited at this time. There are no confirmed reports of transmission of PROS from a parent to a child, and there are no reports of siblings having PROS.[1]

Most people with PROS have a somatic mutation
 in the PIK3CA gene, which is a genetic change that is not inherited, occurring randomly after fertilization (the joining of the egg and the sperm).[1] Somatic mutations occur in cells other than egg and sperm cells (which are called gametes), and ultimately are only present in the cells that originate from the cell in which the mutation occurred. This is called somatic mosaicism. A person with somatic mosaicism cannot pass the mutation on to his/her children when the mutation is not present in the gametes. The siblings of a person with PROS due to somatic mosaicism also are not thought to have an increased risk to have PROS.[1]

Rarely, a person with PROS has a germline mutation (a genetic change in a person's egg or sperm cell), which means the mutation is present in all of that person's cells. However, in the reported cases of germline mutations causing PROS, the mutations have occurred for the first time in the person with PROS and have not been inherited from either parent.[1] These are called de novo mutations. Each child of a person with a de novo germline mutation has a 50% chance of inheriting the mutation. However as noted above, PROS in both a parent and child has not been reported. Siblings of a person with a de novo germline mutation theoretically have a 1% risk to have PROS, due to the possibility of germline mosaicism in a parent.[1]
Last updated: 1/29/2018

A diagnosis of PIK3CA-related overgrowth spectrum (PROS) is often suspected based on characteristic signs and symptoms of the syndromes. For example, megalencephaly-capillary malformation syndrome (MCAP syndrome) can be diagnosed based on findings of megalencephaly and characteristic malformations of the smallest blood vessels (capillaries). CLOVES syndrome can be similarly diagnosed by observing signs and symptoms such as overgrowth, capillary malformations, skin findings, and skeletal abnormalities.[1][8]

A diagnosis of PROS can be confirmed with genetic testing of the PIK3CA gene. However, some people with these syndromes may have normal (negative) genetic testing. This is because the genetic changes (mutations or pathogenic variants) are only in some cells of the body. Therefore, multiple samples of different tissues may need to be tested for the PIK3CA genetic changes. In some cases, even if multiple tissues are tested, the diagnosis is not able to be confirmed with genetic testing.[1]  
Last updated: 1/29/2018

Unfortunately, there is no cure for PIK3CA-related overgrowth spectrum (PROS). However, there are treatment options that can help manage symptoms of the syndromes. People with overgrowth may be treated with surgery to remove growths that are impacting movement. Surgery may also be necessary if there is too much pressure on the brain or to treat skeletal symptoms such as scoliosis. Medications may be used to treat seizures (epilepsy).[1] Researchers are investigating other potential medications that may be used to treat PROS.[9][10] 

People with PROS may be followed by a multi-disciplinary team that may include a neurologist, cardiologist, nephrologist (doctor that helps manage kidney problems), and an orthopedist. Other treatment options may include speech therapy, physical therapy, and special education in school.[1]  
Last updated: 1/29/2018

People with PIK3CA-related overgrowth syndrome (PROS) may struggle with severe overgrowth. This may mean that they require surgery to help remove some of the extra tissue, especially if it is causing trouble in day-to-day life. Unfortunately, the syndromes can also be associated with other health problems that can make daily life difficult.[1][10] If overgrowth affects the brain and creates too much pressure, there can be side-effects such as intellectual disability and developmental delay.[1]  
Last updated: 1/29/2018

Research helps us better understand diseases and can lead to advances in diagnosis and treatment. This section provides resources to help you learn about medical research and ways to get involved.

Patient Registry

  • A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with PIK3CA-related overgrowth spectrum. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. Learn more about registries.

    Registries for PIK3CA-related overgrowth spectrum:
    CLOVES Contact Registry
     

Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.

Organizations Supporting this Disease


These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.

In-Depth Information

  • GeneReviews provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.
  • PubMed is a searchable database of medical literature and lists journal articles that discuss PIK3CA-related overgrowth spectrum. Click on the link to view a sample search on this topic.
  • The University of Cambridge has a resource about segmental overgrowth and opportunities to enroll in a database for future research opportunities. 

Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know.


  1. Mirzaa G, Conway R,Graham JM, and Dobyns WB.. PIK3CA-Related Segmental Overgrowth. GeneReviews. August 15 2013; https://www.ncbi.nlm.nih.gov/books/NBK153722/.
  2. PIK3CA gene. Genetics Home Reference (GHR). August, 2016; https://ghr.nlm.nih.gov/gene/PIK3CA#conditions.
  3. Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, et al. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS). Clin Genet. January, 2017; 91(1):14-21. https://www.ncbi.nlm.nih.gov/pubmed/27426476.
  4. Couto JA, Konczyk DJ, Vivero MP, et al. Somatic PIK3CA Mutations are Present in Multiple Tissues of Facial Infiltrating Lipomatosis. Pediatr Res. November, 2017; 82(5):850-854. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645230/.
  5. Hemihyperplasia-multiple lipomatosis syndrome. Orphanet. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=276280. Accessed 7/10/2018.
  6. Gripp KW, Baker L, Kandula V, Conard K, Scavina M, Napoli JA, Griffin GC, Thacker M, Knox RG, Clark GR, Parker VE, Semple R, Mirzaa G, and Keppler-Noreuil KM. Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation. American Journal of Medical Genetics. October 2016; 170(10):2559-2569. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514817/.
  7. PIK3CA gene. Genetics Home Reference. August 2016; https://ghr.nlm.nih.gov/gene/PIK3CA.
  8. Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Dobyns W, and Biesecker LG. PIK3CA-Related Overgrowth Spectrum (PROS): Diagnostic and Testing Eligibility Criteria, Differential Diagnosis, and Evaluation. American Journal of Medical Genetics. February 2015; 167(2):287-295. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480633/.
  9. Suzuki Y, Enokido Y, Yamada K, Inaba M, Kuwata K, Hanada N, Morishita T, Mizuno S, and Wakamatsu N. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS). Oncotarget. July 11, 2017; 8(28):45470-45483. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542201/.
  10. Keppler-Noreuil KM, Parker VER, Darling TN, and Martinez-Agosto JA. Somatic Overgrowth Disorders of the PI3K/mTOR Pathway & Therapeutic Strategies. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. December 2016; 172(4):402-421. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592089/.